Your browser doesn't support javascript.
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Sormani, Maria Pia; Schiavetti, Irene; Landi, Doriana; Carmisciano, Luca; De Rossi, Nicola; Cordioli, Cinzia; Moiola, Lucia; Radaelli, Marta; Immovilli, Paolo; Capobianco, Marco; Brescia Morra, Vincenzo; Trojano, Maria; Tedeschi, Gioacchino; Comi, Giancarlo; Battaglia, Mario Alberto; Patti, Francesco; Fragoso, Yara Dadalti; Sen, Sedat; Siva, Aksel; Furlan, Roberto; Salvetti, Marco.
  • Sormani MP; Department of Health Sciences, University of Genoa, Genoa, Italy/IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Schiavetti I; Department of Health Sciences, University of Genoa, Genoa, Italy.
  • Landi D; Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
  • Carmisciano L; Department of Health Sciences, University of Genoa, Genoa, Italy.
  • De Rossi N; Centro Sclerosi Multipla, ASST Spedali Civili di Brescia, Montichiari, Italy.
  • Cordioli C; Centro Sclerosi Multipla, ASST Spedali Civili di Brescia, Montichiari, Italy.
  • Moiola L; Department of Neurology, Multiple Sclerosis Center, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Radaelli M; Department of Neurology and Multiple Sclerosis Center, ASST 'Papa Giovanni XXIII', Bergamo, Italy.
  • Immovilli P; Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy.
  • Capobianco M; Department of Neurology, Regional Referral Multiple Sclerosis Centre, University Hospital San Luigi, Torino, Italy.
  • Brescia Morra V; University of Naples Federico II, Naples, Italy.
  • Trojano M; Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy.
  • Tedeschi G; Department of Advanced Medical and Surgical Sciences, University of Campania, Napoli, Italy.
  • Comi G; Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Battaglia MA; Research Department, Italian Multiple Sclerosis Foundation, Genoa, Italy/Department of Life Sciences, University of Siena, Siena, Italy.
  • Patti F; Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, University of Catania, Catania, Italy/Centro Sclerosi Multipla, Policlinico Catania, University of Catania, Catania, Italy.
  • Fragoso YD; Universidade Metropolitana de Santos, Santos, Brazil.
  • Sen S; School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
  • Siva A; School of Medicine, Istanbul University, Cerrahpasa, Istanbul, Turkey.
  • Furlan R; Institute of Experimental Neurology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy/Italian Neuroimmunology Association-AINI, Florence, Italy.
  • Salvetti M; Department of Neuroscience, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy/Unit of Neurology, IRCCS Neuromed, Isernia, Italy.
Mult Scler ; 28(7): 1034-1040, 2022 06.
Article in English | MEDLINE | ID: covidwho-1334706
ABSTRACT

BACKGROUND:

The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available.

OBJECTIVE:

To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test.

METHODS:

We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model.

RESULTS:

Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002).

CONCLUSION:

Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211035318

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211035318